(616 Kb) 【2025】

: Investigating approaches where patients only take the drug for a set period, especially if they achieve a complete response, to avoid unnecessary long-term exposure and side effects. If you'd like, I can:

Toxicities and outcomes of 616 ibrutinib-treated patients in ... - PMC (616 KB)

The study highlighted a few differences between "real-world" patients and those in trials: : Investigating approaches where patients only take the

: Interestingly, the most common reason for stopping the drug was toxicity (intolerance) rather than the leukemia getting worse (disease progression). Provide a breakdown of the used by the

Provide a breakdown of the used by the researchers in this study. Which of these would be most helpful for you?

: Despite the high rate of stopping, the overall survival and progression-free survival (estimated at 35 months) remained excellent. Real-World vs. Clinical Trials